



OPEN ACCESS

EDITED AND REVIEWED BY
Richard D. Emes,
University of Nottingham,
United Kingdom

*CORRESPONDENCE
Peng Liang,
liangpengd@yahoo.com

[†]These authors have contributed equally to this work and share first authorship

SPECIALTY SECTION
This article was submitted to
Computational Genomics,
a section of the journal
Frontiers in Genetics

RECEIVED 04 June 2022
ACCEPTED 11 July 2022
PUBLISHED 17 August 2022

CITATION
Zhang S, Xiao X, Wang Y, Song T, Li C,
Bao H, Liu Q, Sun G, Sun X, Su T, Fu T,
Wang Y and Liang P (2022),
Corrigendum: Developing an immune-
related signature for predicting survival
rate and the response to immune
checkpoint inhibitors in patients
with glioma.
Front. Genet. 13:961153.
doi: 10.3389/fgene.2022.961153

COPYRIGHT
© 2022 Zhang, Xiao, Wang, Song, Li,
Bao, Liu, Sun, Sun, Su, Fu, Wang and
Liang. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Developing an immune-related signature for predicting survival rate and the response to immune checkpoint inhibitors in patients with glioma

Sibin Zhang^{1†}, Xu Xiao^{1†}, Yu Wang², Tianjun Song³, Chenlong Li¹, Hongbo Bao¹, Qing Liu¹, Guiyin Sun¹, Xiaoyang Sun¹, Tianqi Su¹, Tianjiao Fu¹, Yujie Wang¹ and Peng Liang^{1*}

¹Department of Neurosurgery, Harbin Medical University Cancer Hospital, Harbin, China, ²Department of Esophageal Surgery, Harbin Medical University Cancer Hospital, Harbin, China, ³Department of Medicine II, University Hospital LMU Munich, Munich, Germany

KEYWORDS

glioma, bioinformatics signature, prognosis, immune environment, immunotherapy

A Corrigendum on

Developing an immune-related signature for predicting survival rate and the response to immune checkpoint inhibitors in patients with glioma

by Zhang S, Xiao X, Wang Y, Song T, Li C, Bao H, Liu Q, Sun G, Sun X, Su T, Fu T, Wang Y and Liang P (2022). *Front. Genet.* 13:899125. doi: 10.3389/fgene.2022.899125

In the published article, there was an error in [Figure 2](#) as published. The second ROC curve in [Figure 2B](#) and the second KM curve in [Figure 2C](#) are same with the first ROC curve in [Figure 2B](#) and the first KM curve in [Figure 2C](#), respectively. The corrected [Figure 2](#) appears below.

In the published article, there was an error in **Results**, *Immune-Related Signature and the Survival of Patients With Glioma*, **paragraph 1**. This sentence previously stated: “In the TCGA training set, the under areas of 1-year, 3-year and 5-year survival were 0.88, 0.93 and 0.90”

The corrected sentence appears below:

“In the TCGA training set, the under areas of 1-year, 3-year and 5-year survival were 0.88, 0.94 and 0.93”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 2 Immune-related signature effectively predicts the prognosis of patients with glioma. **(A)** Risk score distribution, survival status and expression of 15 hub genes for glioma in low-risk and high-risk groups. **(B)** 1, 3 and 5-year ROC curve analyses. ROC, receiver operating characteristic. **(C)** K-M survival curve analyses.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.